Background: Indoleamine (2,3)-dioxygenase (IDO) catalyses the initial, rate-limiting step in the degradation of the essential amino acid tryptophan. Via tryptophan deprivation, IDO activity suppresses T cell proliferation and differentiation and is thought to be a fundamental immune escape mechanism for tumor cells. Objective and Methods: To investigate the potential role of tryptophan degradation as a prognostic marker, serum tryptophan and kynurenine concentrations and the kynurenine-to-tryptophan ratio (kyn/trp) in 87 patients with malignant melanoma were compared to the course of the disease and to concentrations of the immune activation marker neopterin. Results: Compared to 49 healthy volunteers, the melanoma patients presented with lower tryptophan levels due to accelerated degradation. This was especially true for the subgroups of patients with distant metastases (p = 0.01), though not in patients with lymph node metastases or in patients who had not yet progressed. There existed a positive correlation between kyn/trp and neopterin concentrations (rs = 0.587, p <0.001). In patients who died due to dissemination of the tumor, median tryptophan concentrations were significantly decreased (p = 0.006) and kyn/trp (p = 0.03) and neopterin concentrations (p = 0.002) were higher compared to survivors. In addition, lower tryptophan concentrations as well as higher kyn/trp and neopterin concentrations predicted a shorter survival. Conclusion: Decreased serum tryptophan concentrations and elevated serum neopterin levels can be used as predictive markers for the future course in melanoma patients. Moreover, our data support previous speculations that a higher degree of IDO expression could play a crucial role for tumor progression.

Keywords:
Melanoma, prognostic factor, Tryptophan, Neopterin
1.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57–70.
2.
Mapara MY, Sykes M: Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–1151.
3.
Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163–189.
4.
Brandacher G, Schroecksnadel K, Winkler C, Margereiter R, Fuchs D: Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Curr Drug Metabol 2006;7:599–612.
5.
Taylor MW, Feng GS: Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516–2522.
6.
Pfefferkorn ER: Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984;81:908–992.
7.
Mellor AL, Munn DH: Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809–5813.
8.
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269–1274.
9.
Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000;164:3596–3599.
10.
Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220–225.
11.
Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R: Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107–112.
12.
Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097–1101.
13.
Laich A, Neurauter G, Widner B, Fuchs D: More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002;48:579–581.
14.
Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310–316.
15.
Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, Szabo G, Dierich MP, Wachter H: Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987;41:273–280.
16.
Wirleitner B, Reider D, Ebner S, Böck G, Widner B, Jaeger M, Schennach H, Romani N, Fuchs D: Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 2002;72:1148–1153.
17.
Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG: Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 1991;294:425–435.
18.
Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D: Neopterin is a prognostic parameter in patients with squamous-cell carcinomas of the oral cavity. Int J Cancer 1998;79:476–480.
19.
Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D: Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003;10:1581–1591.
20.
Schroecksnadel K, Winkler C, Fuith LC, Fuchs D: Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005;223:323–329.
21.
Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG: Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691–1696.
22.
Kim CJ, Reintgen DS, Balch CM; AJCC Melanoma Staging Committee: The new melanoma staging system. Cancer Control 2002;9:9–15.
23.
Fuchs D, Weiss G, Reibnegger G, Wachter H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992;29:307–341.
24.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
25.
Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D: Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82–90.
26.
Munn DH, Mellor AL: IDO and tolerance to tumors. Trends Mol Med 2004;10:15–18.
27.
Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H: Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 1990;44:186–189.
28.
Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, Wachter H: Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987:47:4977–4981.
29.
Giusti RM, Maloney EM, Hanchard B, Morgan OSC, Steinberg SM, Wachter H, Williams E, Cranston B, Fuchs D, Manns A: Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic pararesis and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prevent 1996;5:699–709.
30.
Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H: Overexpression of indoleamine 2,3-dioxygenase (IDO) in human inflammatory bowel disease. Clin Immunol 2004;113:47–55.
31.
Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G: Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993;53:260–265.
32.
Gajewski TF: Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006;12:2326s–2330s.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.